Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Monday.
Abeona Therapeutics Stock Down 1.9 %
Shares of ABEO traded down $0.10 during trading hours on Monday, reaching $5.25. 140,200 shares of the company traded hands, compared to its average volume of 222,111. Abeona Therapeutics has a 12-month low of $2.19 and a 12-month high of $5.94. The stock’s fifty day moving average price is $4.80 and its 200 day moving average price is $4.21.
Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last issued its earnings results on Monday, November 13th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.05. Equities research analysts expect that Abeona Therapeutics will post -2.04 earnings per share for the current year.
Institutional Trading of Abeona Therapeutics
Large investors have recently made changes to their positions in the stock. Adage Capital Partners GP L.L.C. lifted its stake in Abeona Therapeutics by 84.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 3,249,994 shares of the biopharmaceutical company’s stock worth $13,682,000 after acquiring an additional 1,488,834 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Abeona Therapeutics during the fourth quarter valued at about $3,544,000. Armistice Capital LLC acquired a new position in Abeona Therapeutics in the 4th quarter worth approximately $3,406,000. AIGH Capital Management LLC increased its holdings in Abeona Therapeutics by 77.7% in the 3rd quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company’s stock worth $4,779,000 after buying an additional 496,278 shares during the period. Finally, Citigroup Inc. increased its holdings in Abeona Therapeutics by 125.0% in the 3rd quarter. Citigroup Inc. now owns 450,000 shares of the biopharmaceutical company’s stock worth $1,894,000 after buying an additional 250,000 shares during the period. 43.97% of the stock is owned by hedge funds and other institutional investors.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company’s lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.